Recombinant tissue plasminogen activator is an approved Food and Drug Administration (FDA) thrombolytic agent for the treatment of AIS [25–27], resulting in improved functional outcome in patients treated soon after an AIS [28–36]. Here, PLAT is linked to androgen insensitivity syndrome.